3 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
- To evaluate the impact of the use of Sylys® Surgical Sealant as an adjunct to standard anastomosis closure techniques on anastomotic leak rate. - To evaluate the impact of the use of Sylys® Surgical Sealant on the overall number of anastomosis-…
The Primary objective is to confirm the maintenance of vigilance with SENS-111.Secondary objectives are:* to confirm the maintenance of working memory, and cognitive function; * to confirm the pharmacodynamics effect of SENS-111 on symptoms…